"Long moments of boredom punctuated by moments of sheer terror" is a
relatively common expression used in reference to war, but it can also
apply to biotech investing, to a limited extent. Stocks like Neurocrine Biosciences (NBIX)
are inarguably driven in large part by relatively infrequent news on
clinical trial outcomes and partnering arrangements, with the shares
left to drift on speculation and overall biotech sentiment in the long
spaces between.
Neurocrine management is certainly not just
sitting on its hands as they work to put '854 into Phase III development
for tardive dyskinesia and Phase II development for Tourette's, and as
partner AbbVie (ABBV)
moves Elagolix through clinical trials in endometriosis and uterine
fibroids. Between final agreement on a Phase III '854 protocol and top
line data from one Phase III endometriosis study, investors still have
important data to look forward to this year, but there will be some long
waits in between.
Continue reading here:
Neurocrine In "Hurry Up And Wait" Mode
No comments:
Post a Comment